Leerink Partners Downgrades RAPT Therapeutics to Market Perform, Announces $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Thomas Smith downgraded RAPT Therapeutics from Outperform to Market Perform and set a price target of $10.

February 21, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Leerink Partners downgraded RAPT Therapeutics to Market Perform and set a $10 price target.
Downgrades by analysts, especially from Outperform to Market Perform, typically lead to negative investor sentiment and can result in a short-term decrease in stock price. The announcement of a $10 price target, depending on the current stock price, might also influence the stock negatively if it suggests a downside.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100